Hansoh Pharmaceutical (03692.HK) Announces HS-10511 Tablet Receives IND Approval for Hypertrophic Cardiomyopathy

Source: Guolon Holdings Limited

Gelonghui November 10thHansoh Pharma(03692.HK) Announcement: HS-10511 Tablets, a Class 1 new drug independently developed by the Company's subsidiaries, Shanghai Hansoh Biomedical Technology Co., Ltd. and Jiangsu Hansoh Pharmaceutical Group Co., Ltd., have received the clinical trial notification issued by the China National Medical Products Administration. It is intended for the treatment of hypertrophic cardiomyopathy, with specific indications to be determined after clinical trials.